The incidence of esophagogastric junction (EGJ) cancer has been on the rise in recent years, and the treatment of Siewert type Ⅱ adenocarcinoma of EGJ (AEG) is still controversial. The core issues are mainly concentrated in the esophagus resection margin, the scope of gastrectomy, the extent of lymph node dissection, and the method of digestive tract reconstruction. With the continuous multidisciplinary discussion and verification for Siewert type Ⅱ AEG at home and abroad, the diagnosis and treatment of Siewert type Ⅱ AEG have become increasingly standardized. The standardization of Siewert type Ⅱ AEG treatment has also been explored through multi-center trials (e.g., CLASS-10) in our country. It is believed that the active advancement of more and more large-scale prospective clinical studies will bring more integration possibilities for communication and cooperation among various disciplines and innovation of new technologies, which will provide more survival benefits to patients.